期刊文献+

中性粒细胞与淋巴细胞亚群比值在非小细胞肺癌临床分期及病理分型中的应用价值研究

Application value of neutrophil to lymphocyte subsets ratios in clinical staging andpathological typing of non-small cell lung cancer
下载PDF
导出
摘要 目的探讨中性粒细胞与淋巴细胞亚群比值在非小细胞肺癌(NSCLC)临床分期及病理分型中的应用价值。方法选取2018年1月至2020年12月在该院住院治疗的经组织病理学确诊的NSCLC患者132例作为NSCLC组。另选取同期在该院体检的健康者85例作为对照组,检测并计算两组研究对象的中性粒细胞与淋巴细胞亚群比值,并进行比较。结果与对照组比较,NSCLC组CD3^(+)T细胞、CD4^(+)T细胞、CD8^(+)T细胞、B细胞、自然杀伤(NK)细胞、CD4^(+)/CD8^(+)明显降低,中性粒细胞与淋巴细胞比值(NLR)、中性粒细胞与CD3^(+)T细胞比值(N/CD3^(+))、中性粒细胞与CD4^(+)T细胞比值(N/CD4^(+))、中性粒细胞与CD8^(+)T细胞比值(N/CD8^(+))、中性粒细胞与B细胞比值(N/B)、中性粒细胞与NK细胞比值(N/NK)明显升高(P<0.05)。与腺癌组相比,鳞癌组NLR、N/CD3^(+)、N/CD4^(+)、N/B、N/NK明显增高(P<0.05)。Ⅰ期组、Ⅱ期组、Ⅲ期组、Ⅳ期组NLR、N/CD3^(+)、N/CD4^(+)、N/CD8^(+)、N/B、N/NK均显著高于对照组(P<0.05),与Ⅰ期组相比,Ⅲ期组和Ⅳ期组N/CD3^(+)、N/CD4^(+)、N/CD8^(+)、N/B均显著增高(P<0.05),CD3^(+)T细胞、B细胞明显降低(P<0.05)。受试者工作特征曲线分析显示,中性粒细胞和淋巴细胞亚群比值的曲线下面积和约登指数分别较相应的淋巴细胞亚群高。基于机器学习的线性支持向量分类器(Linear SVC)算法,将N/CD3^(+)、N/CD4^(+)、N/CD8^(+)、N/B、N/NK指标用于构建NSCLC风险预测模型,结果显示,其曲线下面积可达到0.929,阳性预测值为0.911,阴性预测值为0.787。结论中性粒细胞与淋巴细胞亚群比值与NSCLC的临床分期及病理分型关系密切,N/CD3^(+)、N/CD4^(+)、N/CD8^(+)、N/B、N/NK联合检测的临床诊断效能较高,可以为NSCLC的早期诊断和病情严重程度的评估提供新的诊疗思路。 Objective To explore the application value of neutrophil to lymphocyte subsets ratios in clinical staging and pathological classification of non-small cell lung cancer(NSCLC).Methods A total of 132 NSCLC patients who were hospitalized and diagnosed by histopathology from January 2018 to December 2020 in the hospital were selected as the NSCLC group.Another 85 healthy individuals who underwent physical examinations at the same hospital were selected as the control group,and the neutrophil to lymphocyte subsets ratios of the two study groups were detected and calculated for comparison.Results Compared with the control group,the CD3^(+)T cell,CD4^(+)T cell,CD8^(+)T cell,B cell,natural killer(NK)cell,and CD4^(+)/CD8^(+)in the NSCLC group were significantly reduced,while neutrophil to lymphocyte ratio(NLR),neutrophil to CD3^(+)T cell ratio(N/CD3^(+)),neutrophil to CD4^(+)T cell ratio(N/CD4^(+)),neutrophil to CD8^(+)T cell ratio(N/CD8^(+)),neutrophil to B cell ratio(N/B),and neutrophil to NK cell ratio(N/NK)significantly increased(P<0.05).Compared with adenocarcinoma group,NLR,N/CD3^(+),N/CD4^(+),N/B,and N/NK were higher in the squamous cell carcinoma group(P<0.05).NLR,N/CD3^(+),N/CD4^(+),N/CD8^(+),N/B and N/NK in the stageⅠgroup,the stageⅡgroup,the stageⅢgroup and the stageⅣgroup were significantly higher than those in the control group(P<0.05).Compared with the stageⅠgroup,N/CD3^(+),N/CD4^(+),N/CD8^(+),and N/B in the stageⅢgroup and the stageⅣgroup were significantly increased(P<0.05),while CD3^(+)T cell and B cell were significantly decreased(P<0.05).Receiver operating characteristic curve results showed that the area under the curve and Youden index of the neutrophils to lymphocyte subsets ratios were higher than those of the corresponding lymphocyte subsets.The Linear Support Vector Classification(Linear SVC)algorithm based on machine learning was used to construct a NSCLC risk prediction model using N/CD3^(+),N/CD4^(+),N/CD8^(+),N/B,and N/NK indicators.The results showed that the area under the curve could reach 0.929,with a positive predictive value of 0.911 and a negative predictive value of 0.787.Conclusion The neutrophil to lymphocyte subsets ratios are closely related to the clinical staging and pathological classification of NSCLC.The combined detection of N/CD3^(+),N/CD4^(+),N/CD8^(+),N/B,and N/NK has high clinical diagnostic efficacy and could provide new diagnostic and therapeutic ideas for the early diagnosis and assessment of the severity of NSCLC.
作者 张利改 唱凯 吴宇 裴妤 何远 ZHANG Ligai;CHANG Kai;WU Yu;PEI Yu;HE Yuan(Department of Clinical Laboratory,the First Affiliated Hospital of Army Medical University,Chongqing 400038,China)
出处 《国际检验医学杂志》 CAS 2024年第14期1675-1681,1686,共8页 International Journal of Laboratory Medicine
基金 重庆市科卫联合重点项目(2023ZDXM021)。
关键词 中性粒细胞与淋巴细胞亚群比值 非小细胞肺癌 临床分期 病理分型 neutrophil to lymphocyte subsets ratios non-small cell lung cancer clinical staging pathological classification
  • 相关文献

参考文献3

二级参考文献25

  • 1William D. WHO classification of tumors of the lung, pleura, thymus and heart [ M]. Lyon: IARC, 2015.
  • 2Travis WD, Brambilla E, Noguchi M, et al. The new IASLC/ ATS/ERS international muhidisciplinary lung adenocarcinoma classification [J]. J Thoracic Oncol, 2011,6:244 - 285.
  • 3孟宇红,张建中主译.肺、胸膜、胸腺及心脏肿瘤病理学和遗传学[M].北京:人民卫生出版社,2006.
  • 4Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress[J]. Arch Pathol Leb Med,2015,139(4) :469 -480.
  • 5Sholl LM. Large-cell carcinoma of the lung : a diagnostic category redefined by immunohistochemistry and genomies [J].Curr Opin Pulm Med,2014,20(4) :324 - 331.
  • 6Leighl NB, Rekhtman N, William A, et al. Molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitors:American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline [J]. 2014,32 ( 11 ) :3673 - 3679.
  • 7Hyojin K, Jin-Haeng C. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current dia~aostic testing for ALK rearrangement [ J ]. Transl Lung Cancer Res, 2015,4(2) :149 - 155.
  • 8Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors, impact of genentic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol,2015,10 (9) : 1243 - 1260.
  • 9Zugazagoitia J, Enguita AB, Nunez JA, et al. The new IASLC/ ATS/ERS lung adeuocarcinoma classification from a clinicalperspective : current concepts and future prospects [ J ]. J Thorac Dis,2014,6($5) :$526 - $536.
  • 10Van Schill PE, Sihoe AD, Travis WD, et al. Pathologic classification of adenocarcinoma of lung [ J]. J Surg 0ncol,2013, 108(5) :320 -326.

共引文献160

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部